Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

POXEL Stock Bearish By 27% In The Last 21 Sessions

Loading stream...

(vianews) - shares of poxel (cac 40: poxel.pa) slid by a staggering 27.98% in 21 sessions from €0.97 to €0.70 at 16:07 est on wednesday, after five successive sessions in a row of losses. cac 40 is jumping 0.19% to €7,281.71, after three consecutive sessions in a row of losses.

poxel's last close was €0.68, 79.38% under its 52-week high of €3.28.

about poxel

poxel s.a., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. the company's lead product is twymeeg (imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in japan. it also develops pxl770, an adenosine monophosphate-activated protein kinase enzyme, which is in a phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (nash). poxel s.a. has a licensing agreement with enyo pharma s.a.s. for the development of farnesoid x receptor that is in phase 2a study for the treatment of hepatitis b and nash; and deuterx llc for the development of pxl065, a mitochondrial pyruvate carrier inhibitor, which is in a phase i clinical trial for the treatment of nash. the company was incorporated in 2009 and is headquartered in lyon, france.

earnings per share

as for profitability, poxel has a trailing twelve months eps of €-0.92.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -323.36%.

yearly top and bottom value

poxel's stock is valued at €0.70 at 16:07 est, way below its 52-week high of €3.28 and higher than its 52-week low of €0.67.

moving average

poxel's worth is way below its 50-day moving average of €0.95 and way below its 200-day moving average of €1.54.

volatility

poxel's last week, last month's, and last quarter's current intraday variation average was a negative 5.97%, a negative 2.10%, and a positive 2.47%.

poxel's highest amplitude of average volatility was 5.97% (last week), 2.72% (last month), and 2.47% (last quarter).

revenue growth

year-on-year quarterly revenue growth declined by 99.4%, now sitting on 206k for the twelve trailing months.

more news about poxel (poxel.pa).